Ear Disease

Otonomy Inc (NASDAQ: OTIC), a biopharmaceutical company that focuses on therapies related to diseases and disorders of the ear, reported its third-quarter results and announced an encouraging update to a phase 2 trial. What You Need To Know Otonomy lost 69 cents in its third quarter on revenue of...